Journal

Comparing cell-therapy quotations in Germany and Bulgaria: product before country

Country averages and price multiples are misleading when quotations describe different products, indications, manufacturing steps, services and legal pathways.

Collect dated written quotations before calculating a difference. Each should identify the product or preparation, indication, cell source, manipulation, dose, route, schedule, manufacturer, site and regulatory basis. A shared label such as MSC treatment does not make two offers clinically identical.

Normalise the scope without erasing it. Record assessment, tests, collection, manufacturing, release testing, administration, observation, medicines, rehabilitation, records and follow-up. Preserve the original currency, tax treatment and quotation date. Add travel, companion, accessibility, flexible booking, extra nights and post-return care separately.

Verify quality through source documents rather than national reputation or cost. Check the relevant authority, facility and manufacturing permissions, inspection scope, batch-release specifications, traceability and adverse-event process for the exact product and site. A logo, EU address, higher overhead or lower wage does not establish product quality or outcome equivalence.

Keep evidence independent of price. Compare studies only when population, indication, product, dose, route, comparator and endpoints match. A lower quotation does not prove value, while a higher one does not prove better manufacturing, clinical skill or results. Do not infer a medical-travel corridor from a few heterogeneous advertised packages.

Publish the comparison as a reproducible worksheet with sources, dates, inclusions, exclusions and uncertainty, not as a provider ranking or guaranteed saving. Use the EMA/HMA authorisation checklist for each offer and obtain independent clinical advice. Only after product, pathway and scope match is a price comparison interpretable.

Build an itemised estimate with the cost worksheet. Online information cannot determine candidacy; verify any proposal with an independent qualified clinician.

Sources & further reading

Commercial price observations are heterogeneous and most cell-therapy uses remain investigational. Verify source scope, regulatory status and the proposed care with an independent qualified physician.

Compare cell-therapy evidence, registered studies and published price observations.

StemCellAtlas is a source-first research and cost-planning guide. It separates registry and regulator evidence from heterogeneous commercial observations.

Request written information